Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2007

Open Access 01-06-2007 | Research article

Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus

Authors: Shunsei Hirohata, Yoshiyuki Arinuma, Maki Takayama, Taku Yoshio

Published in: Arthritis Research & Therapy | Issue 3/2007

Login to get access

Abstract

We explored the relationship of antibodies to the whole ribosomal P proteins (P0, P1, and P2) in cerebrospinal fluid (CSF) with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus (SLE). CSF samples were obtained from 71 SLE patients (52 patients with diffuse psychiatric/neuropsychological syndromes [diffuse NP-SLE] and 19 patients with neurological syndromes or peripheral neuropathy [focal NP-SLE]) as well as from 24 patients with non-inflammatory neurological disease. Immunoglobulin G (IgG) antibodies to the C-terminal 22-amino acid ribosomal P synthetic peptide (anti-PC22) and those to purified bovine ribosomal P proteins (P0, P1, and P2) (anti-whole P) were determined by enzyme-linked immunosorbent assay; affinity-purified IgG anti-PC22 were used as the standard. The concentrations of antibodies to epitopes other than the C-terminal 22 amino acids of ribosomal P proteins were calculated by subtracting anti-PC22 from anti-whole P (anti-PEX.C22). CSF anti-whole P levels were significantly elevated in diffuse NP-SLE compared with focal NP-SLE or control patients. By contrast, there were no significant differences in CSF anti-PC22 levels among the three groups. Of note, CSF anti-PEX.C22 levels were significantly elevated in diffuse NP-SLE compared with the other two groups. CSF anti-PEX.C22 levels were not significantly correlated with CSF anti-PC22 levels, but with CSF antibodies against the recombinant ribosomal P0 protein lacking the C-terminal 22 amino acids (C22-depleted rP0). Moreover, levels of CSF anti-PEX.C22 or CSF anti-C22-depleted rP0, but not CSF anti-PC22, were significantly correlated with CSF anti-neuronal cell antibodies (anti-N). These results indicate that CSF IgG antibodies to the epitopes other than the C-terminal 22 amino acids of ribosomal P proteins, which might contain one of the major targets of CSF anti-N, are associated with the development of diffuse NP-SLE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gibson T, Myers AR: Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis. 1975, 35: 398-406.CrossRefPubMed Gibson T, Myers AR: Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis. 1975, 35: 398-406.CrossRefPubMed
2.
go back to reference Harris EN, Hughes GR: Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol. 1985, 8: 251-266. 10.1007/BF00197299.CrossRefPubMed Harris EN, Hughes GR: Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol. 1985, 8: 251-266. 10.1007/BF00197299.CrossRefPubMed
3.
go back to reference Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987, 317: 265-271.CrossRefPubMed Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987, 317: 265-271.CrossRefPubMed
4.
go back to reference Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL: Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991, 90: 54-62. 10.1016/0002-9343(91)90506-S.CrossRefPubMed Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL: Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991, 90: 54-62. 10.1016/0002-9343(91)90506-S.CrossRefPubMed
5.
go back to reference Isshi K, Hirohata S: Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 1483-1490. 10.1002/art.1780390907.CrossRefPubMed Isshi K, Hirohata S: Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 1483-1490. 10.1002/art.1780390907.CrossRefPubMed
6.
go back to reference Golombek SJ, Graus F, Elkon KB: Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum. 1986, 29: 1090-1097. 10.1002/art.1780290906.CrossRefPubMed Golombek SJ, Graus F, Elkon KB: Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum. 1986, 29: 1090-1097. 10.1002/art.1780290906.CrossRefPubMed
7.
go back to reference Isshi K, Hirohata S: Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998, 41: 1819-1827. 10.1002/1529-0131(199810)41:10<1819::AID-ART14>3.0.CO;2-Y.CrossRefPubMed Isshi K, Hirohata S: Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998, 41: 1819-1827. 10.1002/1529-0131(199810)41:10<1819::AID-ART14>3.0.CO;2-Y.CrossRefPubMed
8.
go back to reference Bluestein HG, Zvaifler NJ: Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1976, 57: 509-516.PubMedCentralCrossRefPubMed Bluestein HG, Zvaifler NJ: Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1976, 57: 509-516.PubMedCentralCrossRefPubMed
9.
go back to reference Wilson HA, Winfield JB, Lahita RG, Koffler D: Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum. 1979, 22: 458-462. 10.1002/art.1780220504.CrossRefPubMed Wilson HA, Winfield JB, Lahita RG, Koffler D: Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum. 1979, 22: 458-462. 10.1002/art.1780220504.CrossRefPubMed
10.
go back to reference Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA: Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis. 1990, 49: 249-253.PubMedCentralCrossRefPubMed Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA: Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis. 1990, 49: 249-253.PubMedCentralCrossRefPubMed
11.
go back to reference Bluestein HG, Williams GW, Steinberg AD: Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981, 70: 240-246. 10.1016/0002-9343(81)90756-7.CrossRefPubMed Bluestein HG, Williams GW, Steinberg AD: Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981, 70: 240-246. 10.1016/0002-9343(81)90756-7.CrossRefPubMed
12.
go back to reference Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M: Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest. 1992, 89: 1236-1241.PubMedCentralCrossRefPubMed Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M: Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest. 1992, 89: 1236-1241.PubMedCentralCrossRefPubMed
13.
go back to reference Fabien N, Moreira A, Lavergne JP, Desbos A, Surgey P, Alves de Olivera C, Gonzalo P, Venot A, Bienvenu J, Perrier H, et al: Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins. J Autoimmun. 1999, 13: 103-110. 10.1006/jaut.1999.0291.CrossRefPubMed Fabien N, Moreira A, Lavergne JP, Desbos A, Surgey P, Alves de Olivera C, Gonzalo P, Venot A, Bienvenu J, Perrier H, et al: Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins. J Autoimmun. 1999, 13: 103-110. 10.1006/jaut.1999.0291.CrossRefPubMed
14.
go back to reference Yoshio T, Hirata D, Onda K, Nara H, Minota S: Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005, 32: 34-39.PubMed Yoshio T, Hirata D, Onda K, Nara H, Minota S: Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005, 32: 34-39.PubMed
15.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
16.
go back to reference ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42: 599-608. 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.CrossRef ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42: 599-608. 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.CrossRef
17.
go back to reference Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA, Koffler D: Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med. 1983, 74: 837-844. 10.1016/0002-9343(83)91075-6.CrossRefPubMed Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA, Koffler D: Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med. 1983, 74: 837-844. 10.1016/0002-9343(83)91075-6.CrossRefPubMed
18.
go back to reference Hirohata S, Hirose S, Miyamoto T: Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity. Arch Intern Med. 1985, 145: 1843-1846. 10.1001/archinte.145.10.1843.CrossRefPubMed Hirohata S, Hirose S, Miyamoto T: Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity. Arch Intern Med. 1985, 145: 1843-1846. 10.1001/archinte.145.10.1843.CrossRefPubMed
19.
go back to reference Hirohata S, Miyamoto T: Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990, 33: 644-649. 10.1002/art.1780330506.CrossRefPubMed Hirohata S, Miyamoto T: Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990, 33: 644-649. 10.1002/art.1780330506.CrossRefPubMed
20.
go back to reference Nagai T, Arinuma Y, Yanagida T, Yamamoto K, Hirohata S: Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum. 2005, 52: 847-855. 10.1002/art.20869.CrossRefPubMed Nagai T, Arinuma Y, Yanagida T, Yamamoto K, Hirohata S: Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum. 2005, 52: 847-855. 10.1002/art.20869.CrossRefPubMed
21.
go back to reference Yoshio T, Masuyama J, Minota S, Iwamoto M, Mimori A, Takeda A, Okazaki H, Kano S: Correlation of serum IgG antibodies to recombinant P0 fusion protein with IgG antibodies to carboxyl-terminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-depleted recombinant P0 fusion protein in patients with systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1364-1365.PubMed Yoshio T, Masuyama J, Minota S, Iwamoto M, Mimori A, Takeda A, Okazaki H, Kano S: Correlation of serum IgG antibodies to recombinant P0 fusion protein with IgG antibodies to carboxyl-terminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-depleted recombinant P0 fusion protein in patients with systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1364-1365.PubMed
22.
go back to reference Elkon K, Skelly S, Parnassa A, Moller W, Danho W, Weissbach H, Brot N: Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci USA. 1986, 83: 7419-7423. 10.1073/pnas.83.19.7419.PubMedCentralCrossRefPubMed Elkon K, Skelly S, Parnassa A, Moller W, Danho W, Weissbach H, Brot N: Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci USA. 1986, 83: 7419-7423. 10.1073/pnas.83.19.7419.PubMedCentralCrossRefPubMed
23.
go back to reference DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B: A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001, 7: 1189-1193. 10.1038/nm1101-1189.CrossRefPubMed DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B: A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001, 7: 1189-1193. 10.1038/nm1101-1189.CrossRefPubMed
24.
go back to reference Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, Galeazzi M, Hirohata S, Hoffman IE, Inanc M, et al: Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006, 54: 312-324. 10.1002/art.21539.CrossRefPubMed Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, Galeazzi M, Hirohata S, Hoffman IE, Inanc M, et al: Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006, 54: 312-324. 10.1002/art.21539.CrossRefPubMed
25.
go back to reference Hirohata S, Hayakawa K: Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999, 42: 2729-2730. 10.1002/1529-0131(199912)42:12<2729::AID-ANR35>3.0.CO;2-I.CrossRefPubMed Hirohata S, Hayakawa K: Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999, 42: 2729-2730. 10.1002/1529-0131(199912)42:12<2729::AID-ANR35>3.0.CO;2-I.CrossRefPubMed
Metadata
Title
Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus
Authors
Shunsei Hirohata
Yoshiyuki Arinuma
Maki Takayama
Taku Yoshio
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2007
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2184

Other articles of this Issue 3/2007

Arthritis Research & Therapy 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.